Friederike Scharhag-Rosenberger1,2, Rea Kuehl3,4, Oliver Klassen4, Kai Schommer5, Martina E Schmidt4, Cornelia M Ulrich4,6, Joachim Wiskemann3,4, Karen Steindorf4. 1. Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany. friederike.scharhag-rosenberger@nct-heidelberg.de. 2. Department of Preventive Oncology, National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research Center (DKFZ), Heidelberg, Germany. friederike.scharhag-rosenberger@nct-heidelberg.de. 3. Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany. 4. Department of Preventive Oncology, National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research Center (DKFZ), Heidelberg, Germany. 5. First Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 6. Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Abstract
PURPOSE:Cancer survivors are recommended to perform 150 min/week of moderate or 75 min/week of vigorous aerobic exercise, but it remains unclear how moderate and vigorous intensities can be prescribed. Therefore, it was investigated whether and how intensity prescriptions for healthy adults by the American College of Sports Medicine (ACSM) need to be adapted for breast cancer survivors. METHODS:Fifty-two breast cancer survivors (stage 0-III, age 52 ± 9 years, BMI 25.4 ± 3.5 kg/m2) performed cardiopulmonary exercise tests at the end of primary therapy. Intensity classes defined as percentages of maximal heart rate (HRmax), heart rate reserve (HRR), and maximal oxygen uptake (VO2max) were compared to the ACSM's intensity classes using oxygen uptake reserve as reference. RESULTS: The prescriptions for moderate and vigorous exercise intensities were significantly different between breast cancer survivors and healthy adults when using VO2max (moderate 50-66 vs. 46-63 and vigorous 67-91 vs. 64-90% VO2max) or HRR (moderate 26-50 vs. 40-59 and vigorous 51-88 vs. 60-89 % HRR), but not when using HRmax (moderate 65-76 vs. 64-76 and vigorous 77-94 vs. 77-95% HRmax). CONCLUSIONS: In breast cancer survivors, intensity prescriptions for healthy adults result in considerably too intense training if HRR is used as guiding factor. Prescriptions using VO2max result in a slightly too low exercise intensity, whereas recommendations in percentages of HRmax appear valid. IMPLICATIONS FOR CANCER SURVIVORS: Cancer survivors should not uncritically adopt exercise intensity prescriptions for healthy adults. Specific prescriptions for the studied population are provided.
RCT Entities:
PURPOSE: Cancer survivors are recommended to perform 150 min/week of moderate or 75 min/week of vigorous aerobic exercise, but it remains unclear how moderate and vigorous intensities can be prescribed. Therefore, it was investigated whether and how intensity prescriptions for healthy adults by the American College of Sports Medicine (ACSM) need to be adapted for breast cancer survivors. METHODS: Fifty-two breast cancer survivors (stage 0-III, age 52 ± 9 years, BMI 25.4 ± 3.5 kg/m2) performed cardiopulmonary exercise tests at the end of primary therapy. Intensity classes defined as percentages of maximal heart rate (HRmax), heart rate reserve (HRR), and maximal oxygen uptake (VO2max) were compared to the ACSM's intensity classes using oxygen uptake reserve as reference. RESULTS: The prescriptions for moderate and vigorous exercise intensities were significantly different between breast cancer survivors and healthy adults when using VO2max (moderate 50-66 vs. 46-63 and vigorous 67-91 vs. 64-90% VO2max) or HRR (moderate 26-50 vs. 40-59 and vigorous 51-88 vs. 60-89 % HRR), but not when using HRmax (moderate 65-76 vs. 64-76 and vigorous 77-94 vs. 77-95% HRmax). CONCLUSIONS: In breast cancer survivors, intensity prescriptions for healthy adults result in considerably too intense training if HRR is used as guiding factor. Prescriptions using VO2max result in a slightly too low exercise intensity, whereas recommendations in percentages of HRmax appear valid. IMPLICATIONS FOR CANCER SURVIVORS: Cancer survivors should not uncritically adopt exercise intensity prescriptions for healthy adults. Specific prescriptions for the studied population are provided.
Authors: Lianne B Dolan; Karen Gelmon; Kerry S Courneya; John R Mackey; Roanne J Segal; Kirstin Lane; Robert D Reid; Donald C McKenzie Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-09-22 Impact factor: 4.254
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: J H Wilmore; P R Stanforth; J Gagnon; T Rice; S Mandel; A S Leon; D C Rao; J S Skinner; C Bouchard Journal: Med Sci Sports Exerc Date: 2001-01 Impact factor: 5.411
Authors: Carol Ewing Garber; Bryan Blissmer; Michael R Deschenes; Barry A Franklin; Michael J Lamonte; I-Min Lee; David C Nieman; David P Swain Journal: Med Sci Sports Exerc Date: 2011-07 Impact factor: 5.411
Authors: Lee W Jones; Carolyn J Peddle; Neil D Eves; Mark J Haykowsky; Kerry S Courneya; John R Mackey; Anil A Joy; Vikaash Kumar; Timothy W Winton; Tony Reiman Journal: Cancer Date: 2007-08-01 Impact factor: 6.860
Authors: Hendrik Mugele; Nils Freitag; Jannik Wilhelmi; Yanxiang Yang; Sulin Cheng; Wilhelm Bloch; Moritz Schumann Journal: J Cancer Surviv Date: 2019-02-26 Impact factor: 4.442
Authors: Laurien M Buffart; Maike G Sweegers; Anne M May; Mai J Chinapaw; Jonna K van Vulpen; Rob U Newton; Daniel A Galvão; Neil K Aaronson; Martijn M Stuiver; Paul B Jacobsen; Irma M Verdonck-de Leeuw; Karen Steindorf; Melinda L Irwin; Sandi Hayes; Kathleen A Griffith; Alejandro Lucia; Fernando Herrero-Roman; Ilse Mesters; Ellen van Weert; Hans Knoop; Martine M Goedendorp; Nanette Mutrie; Amanda J Daley; Alex McConnachie; Martin Bohus; Lene Thorsen; Karl-Heinz Schulz; Camille E Short; Erica L James; Ronald C Plotnikoff; Gill Arbane; Martina E Schmidt; Karin Potthoff; Marc van Beurden; Hester S Oldenburg; Gabe S Sonke; Wim H van Harten; Rachel Garrod; Kathryn H Schmitz; Kerri M Winters-Stone; Miranda J Velthuis; Dennis R Taaffe; Willem van Mechelen; Marie José Kersten; Frans Nollet; Jennifer Wenzel; Joachim Wiskemann; Johannes Brug; Kerry S Courneya Journal: J Natl Cancer Inst Date: 2018-11-01 Impact factor: 13.506
Authors: Leonardo H D Messias; Claudio A Gobatto; Wladimir R Beck; Fúlvia B Manchado-Gobatto Journal: Front Physiol Date: 2017-06-08 Impact factor: 4.566
Authors: Marion Kiechle; Ricarda Dukatz; Maryam Yahiaoui-Doktor; Anika Berling; Maryam Basrai; Vera Staiger; Uwe Niederberger; Nicole Marter; Jacqueline Lammert; Sabine Grill; Katharina Pfeifer; Kerstin Rhiem; Rita K Schmutzler; Matthias Laudes; Michael Siniatchkin; Martin Halle; Stephan C Bischoff; Christoph Engel Journal: BMC Cancer Date: 2017-11-10 Impact factor: 4.430
Authors: Neha Bansal; M Jacob Adams; Sarju Ganatra; Steven D Colan; Sanjeev Aggarwal; Rudolf Steiner; Shahnawaz Amdani; Emma R Lipshultz; Steven E Lipshultz Journal: Cardiooncology Date: 2019-12-02